Doxycycline and Cancer
Stop feeling helpless…you still have options!
There are many ways to attack cancer. One of the most commonly held beliefs is that cancer cells contain so many genetic mutations that the only way to deal with them is to destroy or remove them by conventional oncological methods such as surgery, chemotherapy and radiation. New research has shown, however, that by altering one specific oncogene in cancer cells, Myc (pronounced “mick”), one can, in essence, turn “off” certain forms of aggressive malignant cells.
Myc plays an essential role in all cellular life cycles. This protein sends the message for the cell to divide. In normal cells, this protein is only made when it’s the proper time for the cell to divide and multiply. In cancer cells, however, Myc is overproduced which results in uncontrolled and constant cell division and replication. This uncontrolled cellular activity results in tumor growth.
When the Myc oncogene is turned off, cancer cells returned to their normal cell function and the malignancy is halted. Interestingly, it has been found that after Myc-sensitive malignant cells return to normal function, they still retain their predisposition to become malignant. Some believe that this predisposition could explain why certain cancers recur after chemotherapy; if chemotherapy only turns cancer cells dormant, they can easily become cancerous again at a later time.
That’s where doxycycline comes in.
Doxycycline is a tetracycline antibiotic drug commonly used to treat infection. It also has specific anti-Myc, anti-tumor activity. Numerous studies have shown that doxycycline induces tumor apoptosis (programmed cell death) and reduces cancer cell proliferation by down-regulating Myc in malignant cells.